Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
|
| gptkbp:activeIngredient |
gptkb:kanamycin
|
| gptkbp:administeredBy |
injection
oral |
| gptkbp:ATCCode |
J01GB04
|
| gptkbp:CASNumber |
25389-94-0
|
| gptkbp:contraindication |
hypersensitivity to aminoglycosides
|
| gptkbp:discoveredBy |
gptkb:Hamao_Umezawa
|
| gptkbp:discoveredIn |
1957
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:eliminationHalfLife |
2.5 hours
|
| gptkbp:hasMolecularFormula |
C18H36N4O11S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kanamycin sulfate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits protein synthesis
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:producedBy |
gptkb:Streptomyces_kanamyceticus
|
| gptkbp:PubChem_CID |
441369
|
| gptkbp:sideEffect |
nephrotoxicity
ototoxicity |
| gptkbp:solubility |
water soluble
|
| gptkbp:target |
bacterial ribosome
|
| gptkbp:UNII |
UQ695L2GFS
|
| gptkbp:usedFor |
gptkb:Bacteria
meningitis tuberculosis peritonitis sepsis urinary tract infection |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:kanamycin
|
| gptkbp:bfsLayer |
6
|